You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Evaluation of the Antigenicity of Black Restricted FVIII Haplotypes and Haplotype

    SBC: Haplomics            Topic: NIMHD

    Evaluation of the Antigenicity of Black-Restricted Haplotypes of Factor VIII ABSTRACT About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Such patients, who are termed inhibitor patients, are typically treated with so called bypassing agents such as recombinant (r) FVIIa and FEIBA. Bypassing agents are mor ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: NIGMS

    DESCRIPTION: Glycans have several distinct properties that make them excellent targets for disease biomarkers. Firstly, the location of the glycans on the cell surface makes them the first point of contact of cellular interactions and thus crucial in thecontrol of normal metabolic processes. Cell surface molecules are also strategically exposed for surveillance by the immune system allowing for t ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Reduce the Risk: An Affect Management Program for HIV Prevention

    SBC: VIRTUALLY BETTER INC            Topic: NIMH

    DESCRIPTION (provided by applicant): The proposed project, titled Reduce the Risk: An Affect Management Program for HIV Prevention, will examine the use of immersive virtual reality technology as an intervention tool for HIV Prevention with adolescents. Adolescents are at risk for contracting HIV. Affect dysregulation is common among adolescents. Research has demonstrated connections between poor ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. System for multidimensional analysis of growth and migration of neurons and neuro

    SBC: Inhibikase Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibikase Therapeutics is a clinical stage, biopharmaceutical company that has developed a host- targeted mechanism of action to treat AIDS-related and drug-induced progressive multifocal leukoencephalopathy (PML). PMLis a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the mid-1980s ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Drug Resistant HIV: Novel Target Validation and Small Molecule Lead Discovery

    SBC: GEOVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): HIV/AIDS remains a major health problem and there is a need for effective and durable HIV vaccines. Establishing potent and durable antibodies (Ab) that have neutralizing and non-neutralizing mechanisms can contribute to the prevention of mucosal HIV infection. Findings from the recent RV144 trial have highlighted a significant role for protective non-neutraliz ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Intraoperative imaging of breast cancer margins using Polarization Subtraction Te

    SBC: LUMAMED, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): LumaMed LLC proposes developing LumaScan , an innovative, cost effective and easy to use device for visualizing tumor margins during Breast Conservation Surgery (BCS), a method that is used in about 60-70% percent of breast cancer surgeries. Currently, breast tumors are approximately located using methods such as MRI or CT in a preoperative procedure. During s ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Automating Directly Observed Therapy as a Platform Technology

    SBC: METACLIPSE THERAPEUTICS CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Triple negative breast cancer (TNBC), which includes tumors lacking estrogen, progesterone, and HER-2 receptor proteins, represents 15-20% of all breast cancer diagnoses in the US, and is one of the most challenging cancers for developing an effective therapy post tumor resection. Even with conventional radiation and chemotherapy regimens, patients have poor pr ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a TAVI Device with a Reduced Crossing Profile

    SBC: ABEOME CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is considered the number one health problem in the US and Europe, affecting 10% to 30% of adult populations. Obese individuals are more likely to acquire a variety of secondary diseases including diabetes, heartproblems, immune deficiencies, some types of cancer, and osteoarthritis and they die younger than non-obese individuals. Obesity results from th ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Interventions for Mild Traumatic Brain Injury

    SBC: JYANT Technologies, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): There is a great need for new therapies for Crohn's disease (CD), which is a chronic, relapsing and tissue destructive inflammatory bowel disease (IBD). Estimates indicate that there are gt 1 million annual cases of IBDin the United States, 50% of which involve CD. Our primary objective is to develop a biologic that can be used to better treat and reduce t ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiat

    SBC: Aruna Biomedical, Inc.            Topic: NIEHS

    SUMMARY The overarching objective of this Phase I project is to determine the feasibility of developing both focused and broad toxicity metabolomic assays for three neural development associated windows of susceptibility (WOS) for human development. Epidemiological and laboratory studies have identified numerous chemicals suspected to be developmental neurotoxicants. These range from heavy metals ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government